Letter

Safety of thalidomide

BMJ 1994; 308 doi: 10.1136/bmj.308.6941.1437b (Published 28 May 1994)
Cite this as: BMJ 1994;308:1437.3

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. C L Crawford
  1. Department of Anatomy, Charing Cross and Westminster Medical School, London W6 8RF.

    EDITOR, - Use of thalidomide only on a named patient basis does not necessarily mean that patients are protected from its side effects, as implied by Baroness Cumberlege, the junior health minister.1 According to Sir William Asscher, the former chairman of the Committee on the Safety of Medicines, “the companies who supply a drug for named patient use are not required by law …

    Access to the full text of this article requires a subscription or payment

    Subscribe

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    Rapid responses

    THIS WEEK'S POLL

    BMJ most popular